The Company
The Company
Promore Pharma in Brief
Vision and Strategy
Market
Team
Board of Directors
Projects
Projects
Ropocamptide – Healing of Chronic Wounds
Publications
Investors
Investors
Promore Pharma on Nasdaq First North Growth Market
Certified Adviser
The Share
Shareholders
Warrant Programs
Share capital development
Analysts
Financial Reports
Press Releases
Prospectuses
Presentations and Events
Calendar
Subscribe
Corporate Governance
Corporate Governance
Corporate Governance
General Meeting
General Meetings
Nomination Committee
Nomination Committees
The Board of Directors
Board of Directors
The Management
Management
Remunerations and Remuneration Committee
Auditor and Audit Committee
Articles of Association
Certificate of Registration
Media
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Contact
Office
Investors
Media
Svenska
The Company
Promore Pharma in Brief
Vision and Strategy
Market
Team
Board of Directors
Projects
Ropocamptide – Healing of Chronic Wounds
Publications
Investors
Promore Pharma on Nasdaq First North Growth Market
Certified Adviser
The Share
Shareholders
Warrant Programs
Share capital development
Analysts
Financial Reports
Press Releases
Prospectuses
Presentations and Events
Calendar
Subscribe
Corporate Governance
Corporate Governance
General Meeting
General Meetings
Nomination Committee
Nomination Committees
The Board of Directors
Board of Directors
The Management
Management
Remunerations and Remuneration Committee
Auditor and Audit Committee
Articles of Association
Certificate of Registration
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Office
Investors
Media
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Erik Magnusson
Chief Financial Officer (CFO)
+46 70 856 52 45
Press Releases
All press releases
Regulatory press releases
Non-regulatory press releases
All years
2023
2022
2021
2020
2019
2018
2017
2016
2015
2013
September 18, 2023
NOTICE OF EXTRAORDINARY GENERAL MEETING PROMORE PHARMA AB (PUBL)
August 30, 2023
Interim report January – June 2023
August 16, 2023
Promore Pharma engages Erik Penser Bank as liquidity provider
June 27, 2023
Report from the Annual General Meeting of Promore Pharma AB held on 27 June 2023
June 22, 2023
Promore Pharma reduces costs and explores the conditions for a reverse acquisition
May 25, 2023
Promore Pharma’s AGM related Documents Published
May 23, 2023
Interim report January – March 2023
May 9, 2023
Promore Pharma’s Annual Report 2022
April 20, 2023
Promore Pharma AB changes the AGM date to June 27
April 20, 2023
Invitation to a presentation of the results from Promore Pharma’s clinical trial PHSU05
April 20, 2023
Promore Pharma reports outcome from clinical Phase II study with ensereptide
February 28, 2023
Year-end report, 2022
February 27, 2023
Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Fourth Quarter 2022
February 27, 2023
Promore Pharma reaches the Clean File milestone in its phase II clinical trial with ensereptide
November 29, 2022
Interim report January – September 2022
November 24, 2022
Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Third Quarter 2022
November 23, 2022
Nomination Committee Appointed for the Annual General Meeting 2023 in Promore Pharma
November 1, 2022
Promore Pharma provides an update on the Phase II clinical trial with ensereptide
August 30, 2022
Promore Pharma Interim report January – June 2022
August 23, 2022
Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Second Quarter 2022
August 10, 2022
Promore Pharma granted EU patent regarding treatment of chronic wounds
June 13, 2022
The last clinic visit conducted in Promore Pharma’s phase II study of ensereptide
May 17, 2022
Report from the Annual General Meeting of Promore Pharma AB held on 17 May 2022
May 17, 2022
Promore Pharma — interim report January-March 2022
May 13, 2022
Invitation to Conference Call regarding Promore Pharma’s Interim Report for the First Quarter 2022
April 26, 2022
Promore Pharma’s Annual Report 2021 and AGM related Documents Published
April 12, 2022
NOTICE OF ANNUAL GENERAL MEETING PROMORE PHARMA AB (PUBL)
March 17, 2022
Promore Pharma has reached recruitment goal in clinical trial of ensereptide
February 16, 2022
Interim report January – December 2021
February 16, 2022
First patient recruited to Promore Pharma’s clinical trial regarding scarring according to plan
February 9, 2022
Invitation to Conference Call regarding Promore Pharma’s Year-end Report 2021
January 31, 2022
Promore Pharma deregisters warrants
December 8, 2021
Promore Pharma granted US patent regarding treatment of chronic wounds
November 23, 2021
Interim report January – September 2021
November 19, 2021
Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Third Quarter 2021
November 16, 2021
Nomination Committee Appointed for the Annual General Meeting 2022 in Promore Pharma
November 9, 2021
Promore Pharma receives permits to start a phase II clinical trial regarding scar prevention
October 25, 2021
Promore Pharma announces that scientific article has been published on clinical study results with ropocamptide for venous leg ulcers
September 13, 2021
Promore Pharma receives delivery of hyaluronic acid from Italian manufacturer Fidia
August 24, 2021
Interim report January – June 2021
August 17, 2021
Invitation to Conference Call regarding Promore Pharma’s Q2 Report 2021
July 20, 2021
The rights issue is registered and the trading in Paid Subscription Shares ceases
June 22, 2021
Outcome in Promore Pharma’s rights issue
June 2, 2021
Promore Pharma publishes prospectus
May 27, 2021
Promore Pharma informs about the last day of trading to receive subscription rights
May 27, 2021
Interim report January – March 2021
May 27, 2021
Report from an extra General Meeting of Promore Pharma AB held on 27 May 2021
May 27, 2021
Report from the Annual General Meeting of Promore Pharma AB held on 27 May 2021
May 26, 2021
Promore Pharma participates in “Småbolagsdagarna 2021”, an event organized by Aktiespararna
May 17, 2021
Invitation to Conference Call regarding Promore Pharma’s Q1 Report 2021
May 12, 2021
Promore Pharma is granted a US patent regarding skin scarring
May 10, 2021
Notice of Extraordinary General Meeting in Promore Pharma AB (publ)
May 7, 2021
Promore Pharma AB intends to carry out a fully secured rights issue in order to implement the new strategy
May 6, 2021
Promore Pharma’s Annual Report 2020 and AGM related Documents Published
April 28, 2021
Promore Pharma signs agreement on production of hyaluronic acid with Italian manufacturer Fidia
April 27, 2021
NOTICE OF ANNUAL GENERAL MEETING PROMORE PHARMA AB (PUBL)
March 31, 2021
Promore Pharma comments on media reports about ensereptide
March 31, 2021
Promore Pharma deregisters warrants
March 31, 2021
Promore Pharma updates its strategy and focuses on scar prevention
February 23, 2021
Year-end report 2020
February 16, 2021
Invitation to Presentation of Promore Pharma’s Year-end report for 2020
January 20, 2021
Promore Pharma changes Certified Adviser to Erik Penser Bank AB
November 25, 2020
Promore Pharma participates at “Aktiespararna’s Stora Aktiedagen”
November 24, 2020
Interim report January – September 2020
November 20, 2020
Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Third Quarter 2020
November 20, 2020
Clarification of outcome in the clinical trial HEAL LL-37
November 19, 2020
Promore Pharma announces positive results from Phase IIb study of ropocamptide in the treatment of venous leg ulcers
October 27, 2020
Nomination Committee Appointed for the Annual General Meeting 2021 in Promore Pharma
August 25, 2020
Promore Pharma AB (publ) Interim report January – June 2020
August 19, 2020
Invitation to Presentation of Promore Pharma’s Interim Report for the Second Quarter 2020
July 14, 2020
Promore Pharma is Granted a Patent for ropocamptide in the US
May 28, 2020
Promore Pharma Appoints Erik Magnusson as Chief Financial Officer
May 26, 2020
Report from the Annual General Meeting of Promore Pharma AB held on 26 May 2020
May 26, 2020
Promore Pharma AB (publ) Interim report January – March 2020
May 25, 2020
Invitation to Conference Call regarding Promore Pharma’s Interim Report for the First Quarter 2020
May 5, 2020
Promore Pharma’s Annual Report 2019 Published
April 22, 2020
Notice of Annual General Meeting in Promore Pharma AB (publ)
April 2, 2020
Promore Pharma´s CFO leaves the company in 2020
March 24, 2020
Promore Pharma reached the targeted number of patients completing treatment in the HEAL LL-37 Phase IIb clinical trial
February 18, 2020
Promore Pharma AB (publ) Year-end report 2019
February 13, 2020
Invitation to Presentation of Promore Pharma’s Year-end report for 2019
December 10, 2019
Promore Pharma has finalized recruitment of patients in HEAL LL-37 early
December 2, 2019
Promore Pharma’s rights issue completed
November 22, 2019
Promore Pharma publishes supplementary prospectus in connection with the ongoing rights issue
November 22, 2019
Promore Pharma AB (publ) Interim report January – September 2019
November 12, 2019
Promore Pharma is granted a patent for PXL01 in the US
November 12, 2019
Promore Pharma publishes prospectus in connection with rights issue
October 22, 2019
Report from the Extraordinary Shareholders’ Meeting of Promore Pharma AB held on 22 October 2019
October 21, 2019
Promore Pharma engages ABG Sundal Collier as liquidity provider
October 17, 2019
Nomination Committee Appointed for the Annual General Meeting 2020 in Promore Pharma
October 7, 2019
Notice of Extraordinary Shareholders’ Meeting in Promore Pharma AB (publ)
October 6, 2019
Promore Pharma Rights issue – correction of date
October 4, 2019
Promore Pharma Promore Pharma carries out a rights issue of approximately SEK 75 million, underwritten up to 80 percent, and intends to publish its interim report early
August 28, 2019
Promore Pharma AB (publ) Interim report January – June 2019
August 27, 2019
Promore Pharma is granted a patent for LL-37 in Japan
August 23, 2019
Invitation to Presentation of Promore Pharma’s Interim report for the second quarter 2019
June 20, 2019
Promore Pharma has recruited half of the patients in HEAL LL-37
May 21, 2019
Report from the Annual General Meeting of Promore Pharma AB held on 21 May 2019
May 21, 2019
Promore Pharma AB (publ) Interim report January – March 2019
May 15, 2019
Invitation to Presentation of Promore Pharma’s Interim report for the first quarter 2019
April 16, 2019
Notice of Annual General Meeting in Promore Pharma AB (publ)
February 26, 2019
Promore Pharma AB (publ) Year-end report 2018
February 20, 2019
Invitation to Presentation of Promore Pharma’s Year-end report for 2018
February 1, 2019
Promore Pharma modifies its Phase III trial of PXL01 and expands the number of clinics in the study
January 31, 2019
Subscription price for Promore Pharma’s warrants TO1 determined
December 17, 2018
PharmaResearch Products Ltd use call option in Promore Pharma
November 23, 2018
Promore Pharma AB (publ) Interim report January – September 2018
November 19, 2018
Promore Pharma receives approval for Phase III study with PXL01 in India
November 9, 2018
Nomination Committee Appointed for the Annual General Meeting 2019 in Promore Pharma
October 23, 2018
Promore Pharma has had a successful meeting with the FDA regarding PXL01
October 1, 2018
Promore Pharma has enrolled first patient in HEAL LL-37 in Poland
September 6, 2018
Promore Pharma has conducted Investigator Meeting for HEAL LL-37 in Poland
September 3, 2018
Promore Pharma Plans to Expand Indications of Therapeutic Peptide PXL01 in the Field of Dermal Scarring
August 22, 2018
Promore Pharma receives approval for Phase IIb trial with LL-37 in Poland
August 20, 2018
Interim report January – June 2018
August 14, 2018
Invitation to Presentation of Promore Pharma’s Interim report for the second quarter 2018
July 3, 2018
Promore Pharma receives approval for Phase IIb trial with LL-37
May 16, 2018
Report from the Annual General Meeting of Promore Pharma AB held on 16 May 2018
May 16, 2018
Promore Pharma AB (publ) Interim report January – March 2018
May 9, 2018
Invitation to Presentation of Promore Pharma’s Interim report for the first quarter 2018
May 7, 2018
Promore Pharma Out-licenses PXL01 for Spinal Surgery to PharmaResearch Products Ltd
April 25, 2018
Promore Pharma 2017 Annual report published
April 19, 2018
Västra Hamnen Corporate Finance Initiates Coverage on Promore Pharma
April 11, 2018
Notice of Annual General Meeting in Promore Pharma AB (publ)
April 4, 2018
Two new smart-phone based imaging products have been adopted by Promore Pharma AB
February 15, 2018
Promore Pharma Regains Rights for PXL01 Manufacturing
February 6, 2018
Year-end report 2017
February 1, 2018
Promore Pharma is granted a patent for PXL01 in the US
January 2, 2018
Promore Pharma Adjusts Plans for PXL01 in North America
November 21, 2017
Interim report January – September 2017
November 14, 2017
Promore Pharma Signs Out-licensing Agreement with Transdermal Therapeutic Technologies for its Peptide DPK-060
October 31, 2017
Promore Pharma Signs Agreement with CRO PCG Clinical Services
October 30, 2017
Promore Pharma Completes Extensive European Collaboration Regarding DPK-060
September 21, 2017
Promore Pharma Signs Manufacturing Agreement with APL
September 12, 2017
Promore Pharma presents at the symposium for hard-to-heal wounds in connection with Nordic Life Science Days
August 30, 2017
Interim report January – June 2017
July 4, 2017
Promore Pharma starts trading on Nasdaq First North on 6 July 2017
June 30, 2017
Promore Pharma awaiting approval from Nasdaq First North in next week
June 26, 2017
New share issue in Promore Pharma raises 76 MSEK ahead of listing on Nasdaq First North
June 7, 2017
Promore Pharma Carries Out a Share Issue Prior to Listing on Nasdaq First North
May 19, 2017
Interim report January – March 2017
May 17, 2017
Promore Pharma AB files phase III clinical trial application in India
April 26, 2017
Promore Pharma AB elects Marianne Dicander Alexandersson as New Board Member and outlines plans for IPO
December 21, 2016
Promore Pharma and Cellastra Inc. Announce Phase III Clinical Collaboration to Develop Therapeutic Peptide PXL01 for the US Market
December 15, 2016
Promore Pharma is Seeking an Office Manager in Stockholm
August 22, 2016
New Chief Financial Officer in Promore Pharma
July 8, 2016
Promore Pharma Announces a Strategic Collaboration with Technomark Life Sciences
July 5, 2016
Pergamum AB and Lipopeptide AB Change Name to Promore Pharma
May 31, 2016
Promore Pharma Obtains Positive Feedback in Dialogue with The Medical Products Agency of Sweden
March 8, 2016
Lipopeptide AB Announces a Strategic Collaboration with Pharmaresearch Products LTD
May 28, 2015
Pergamum AB Announces Ownership Restructuring
October 10, 2013
Pergamum Announces Final Data from Phase I/II Study in Patients with Chronic Leg Ulcers
June 27, 2013
Pergamum Reports Positive Follow-Up Data from a Phase II Clinical Trial of PXL01 for Prevention of Post-Surgical Adhesions
February 8, 2013
Pergamum Announces a Strategic Collaboration with Cadila Pharmaceuticals Ltd.
